Novo Nordisk Stock Plummets 18% Following Weak 2026 Forecast

Novo Nordisk shares plummeted 18% in Copenhagen after the company forecasted a decline in sales and profit for 2026.CEO Mike Doustdar presented the cautious outlook following a year of layoffs and price drops, despite the successful USA launch of Wegovy pills.Analysts Lars Söderfjell and Per Hansen suggest the firm is using a conservative strategy to manage market expectations while investors prioritize growth.